{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T05:02:46Z","timestamp":1648616566751},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["opencardiovascularmedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOCMJ"],"published-print":{"date-parts":[[2017,11,17]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of this study was to compare the efficacy and tolerability of barnidipine, a strong lipophilic calcium channel blocker, in younger (\u226455 for efficacy or &lt;65 years for adverse events) versus older (&gt;55 or \u226565 years) patients with uncomplicated hypertension.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>20,275 patients received barnidipine, 10 or 20 mg\/day, as monotherapy or in combination with other antihypertensive drug(s) in the observational BArnidipine real-life Safety and tolerability In Chronic HyperTension (BASIC-HT) study. Efficacy and tolerability were assessed over a 3-month period. The present paper describes results from prespecified subgroup analyses by age not reported elsewhere.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Both age groups showed a clinically meaningful decrease in blood pressure (BP) over time (p&lt;0.0001). The mean systolic and diastolic BP after approximately 3 months of barnidipine therapy was well below the target value of &lt;140\/90 mmHg for individual patients, with no notable differences between age groups. The decrease in mean pulse pressure was greater in patients &gt;55 years (-10.8 mmHg) than in patients \u226455 years (-8.7 mmHg) (p&lt;0.0001) and the proportion of patients with pulse pressure &gt;60 mmHg decreased from 61.1% at baseline to 24.8% at Visit 3 in patients &gt;55 years and from 47.7% to 16.5% in patients \u226455 years (p&lt;0.0001).<\/jats:p>\n                    <jats:p>The overall incidence of adverse events was low, leading to treatment discontinuation in only 3.0-3.6% of patients. Peripheral edema, a common adverse effect with calcium channel blockers in clinical practice, was reported by 2.7% of patients aged &lt;65 years and by 4.6% of patients aged \u226565 years.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The efficacy and tolerability profiles of barnidipine as monotherapy or in combination with other antihypertensive drugs were shown to be favorable in both younger and older patients in a real-life practice setting. Randomized double-blind controlled studies are needed to confirm these results.<\/jats:p>\n                <\/jats:sec>","DOI":"10.2174\/1874192401711010120","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T06:14:38Z","timestamp":1510899278000},"page":"120-132","update-policy":"http:\/\/dx.doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barnidipine Real-Life Efficacy and Tolerability in Arterial Hypertension: Results from Younger and Older Patients in the BASIC-HT Study"],"prefix":"10.2174","volume":"11","author":[{"given":"Robert","family":"Lins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"De Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Cooper-DeHoff RM, Pepine CJ. \n                    Metabolic syndrome and cardiovascular disease: Challenges and opportunities. \n                    Clin Cardiol  \n                    2007; \n                    30\n                    (12)\n                    : 593-7.","DOI":"10.1002\/clc.7"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hayden MR, Sowers JR. \n                    Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. \n                    J Am Soc Hypertens  \n                    2008; \n                    2\n                    (4)\n                    : 239-66.","DOI":"10.1016\/j.jash.2007.12.002"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Velagaleti RS, Vasan RS. \n                    Heart failure in the twenty-first century: Is it a coronary artery disease or hypertension problem? \n                    Cardiol Clin  \n                    2007; \n                    25\n                    (4)\n                    : 487-495, v.","DOI":"10.1016\/j.ccl.2007.08.010"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Law MR, Morris JK, Wald NJ. \n                    Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. \n                    BMJ  \n                    2009; \n                    338\n                    : b1665.","DOI":"10.1136\/bmj.b1665"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Moran AE, Odden MC, Thanataveerat A, et al. \n                    Cost-effectiveness of hypertension therapy according to 2014 guidelines. \n                    N Engl J Med  \n                    2015; \n                    372\n                    (5)\n                    : 447-55.","DOI":"10.1056\/NEJMsa1406751"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. \n                    2013 ESH\/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). \n                    J Hypertens  \n                    2013; \n                    31\n                    (7)\n                    : 1281-357.","DOI":"10.1097\/01.hjh.0000431740.32696.cc"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Kotseva K, Wood D, De Bacquer D, et al. \n                    EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. \n                    Eur J Prev Cardiol  \n                    2016; \n                    23\n                    (6)\n                    : 636-48.","DOI":"10.1177\/2047487315569401"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Wolf-Maier K, Cooper RS, Banegas JR, et al. \n                    Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. \n                    JAMA  \n                    2003; \n                    289\n                    (18)\n                    : 2363-9.","DOI":"10.1001\/jama.289.18.2363"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Yang F, Qian D, Hu D. \n                    Prevalence, awareness, treatment, and control of hypertension in the older population: Results from the multiple national studies on ageing. \n                    J Am Soc Hypertens  \n                    2016; \n                    10\n                    (2)\n                    : 140-8.","DOI":"10.1016\/j.jash.2015.11.016"},{"key":"ref10","unstructured":"National Clinical Guideline Centre Hypertension: The clinical management of primary hypertension in adults Clinical Guideline 127 Methods, evidence, and recommendations Commissioned by the National Institute for Health and Clinical Excellence \n                    2011.\n                    \n                 Available at: https:\/\/www.nice.org.uk\/guidance\/cg127"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"James PA, Oparil S, Carter BL, et al. \n                    2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). \n                    JAMA  \n                    2014; \n                    311\n                    (5)\n                    : 507-20.","DOI":"10.1001\/jama.2013.284427"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"van Zwieten PA. \n                    The pharmacological properties of lipophilic calcium antagonists. \n                    Blood Press Suppl  \n                    1998; \n                    2\n                    : 5-9.","DOI":"10.1080\/080370598438999"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Malhotra HS, Plosker GL. \n                    Barnidipine. \n                    Drugs  \n                    2001; \n                    61\n                    (7)\n                    : 989-96.","DOI":"10.2165\/00003495-200161070-00007"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Spieker C. \n                    Efficacy and tolerability of once-daily barnidipine in the clinical management of patients with mild to moderate essential hypertension. \n                    Blood Press Suppl  \n                    1998; \n                    1\n                    : 15-21.","DOI":"10.1080\/080370598438555"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Argenziano L, Izzo R, Iovino G, et al. \n                    Distinct vasodilation, without reflex neurohormonal activation, induced by barnidipine in hypertensive patients. \n                    Blood Press Suppl  \n                    1998; \n                    1\n                    : 9-14.","DOI":"10.1080\/080370598438546"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Ruilope LM, Coca A. \n                    The role of combination therapy in the treatment of hypertension. \n                    Blood Press Suppl  \n                    1998; \n                    1\n                    : 22-6.","DOI":"10.1080\/080370598438564"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Parati G, Giglio A, Lonati L, et al. \n                    Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-group study. \n                    Clin Ther  \n                    2010; \n                    32\n                    (7)\n                    : 1270-84.","DOI":"10.1016\/j.clinthera.2010.06.021"},{"key":"ref18","unstructured":"Naber FB, H\u00e4ge R, Mortelmans J. \n                    Barnidipine monotherapy and combination therapy in older patients with essential hypertension: A long-term study. \n                    Int J Clin Pract Suppl  \n                    2000; \n                    114\n                    (114)\n                    : 27-35."},{"key":"ref19","unstructured":"Otterstad JE, Ruilope LM. \n                    Treatment of hypertension in the very old. \n                    Int J Clin Pract Suppl  \n                    2000; \n                    114\n                    (114)\n                    : 10-9."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"van der Velden JW, Beudeker HJ, Nishi M. \n                    Diversity and intensity of adverse events in the treatment of hypertension with barnidipine. \n                    Blood Press Suppl  \n                    1998; \n                    1\n                    : 27-9.","DOI":"10.1080\/080370598438573"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Mancia G, Parodi A, Merlino L, Corrao G. \n                    Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. \n                    J Hypertens  \n                    2011; \n                    29\n                    (5)\n                    : 1012-8.","DOI":"10.1097\/HJH.0b013e32834550d0"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Fogari R, Zoppi A, Derosa G, et al. \n                    Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. \n                    J Hum Hypertens  \n                    2007; \n                    21\n                    (3)\n                    : 220-4.","DOI":"10.1038\/sj.jhh.1002140"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Messerli FH. \n                    Vasodilatory edema: A common side effect of antihypertensive therapy. \n                    Curr Cardiol Rep  \n                    2002; \n                    4\n                    (6)\n                    : 479-82.","DOI":"10.1007\/s11886-002-0110-9"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Lins R, Marckx P, Vandebeek R, Vanhoutvinck C, Neuville O. \n                    Barnidipine real-life tolerability in arterial hypertension: Results from the BASIC-HT study. \n                    Acta Clin Belg  \n                    2015; \n                    70\n                    (4)\n                    : 244-50.","DOI":"10.1179\/2295333715Y.0000000012"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Fogari R, Malamani GD, Zoppi A, et al. \n                    Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: A double-blind, randomized, parallel-group study. \n                    Curr Ther Res  \n                    2000; \n                    61\n                    : 850-62.","DOI":"10.1016\/S0011-393X(00)90012-2"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Sica D. \n                    Calcium channel blocker-related periperal edema: Can it be resolved? \n                    J Clin Hypertens (Greenwich)  \n                    2003; \n                    5\n                    (4)\n                    : 291-4.","DOI":"10.1111\/j.1524-6175.2003.02402.x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Benetos A, Safar M, Rudnichi A, et al. \n                    Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population. \n                    Hypertension  \n                    1997; \n                    30\n                    (6)\n                    : 1410-5.","DOI":"10.1161\/01.HYP.30.6.1410"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Blacher J, Staessen JA, Girerd X, et al. \n                    Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. \n                    Arch Intern Med  \n                    2000; \n                    160\n                    (8)\n                    : 1085-9.","DOI":"10.1001\/archinte.160.8.1085"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Briet M, Boutouyrie P, Laurent S, London GM. \n                    Arterial stiffness and pulse pressure in CKD and ESRD. \n                    Kidney Int  \n                    2012; \n                    82\n                    (4)\n                    : 388-400.","DOI":"10.1038\/ki.2012.131"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. \n                    Optimisation of antihypertensive treatment by crossover rotation of four major classes. \n                    Lancet  \n                    1999; \n                    353\n                    (9169)\n                    : 2008-13.","DOI":"10.1016\/S0140-6736(98)07614-4"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Materson BJ, Reda DJ, Cushman WC. \n                    Department of veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. \n                    Am J Hypertens  \n                    1995; \n                    8\n                    (2)\n                    : 189-92.","DOI":"10.1016\/0895-7061(94)00196-I"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Chi C, Tai C, Bai B, et al. \n                    Angiotensin system blockade combined with calcium channel blockers is superior to other combinations in cardiovascular protection with similar blood pressure reduction: A meta-analysis in 20,451 hypertensive patients. \n                    J Clin Hypertens (Greenwich)  \n                    2016; \n                    18\n                    (8)\n                    : 801-8.","DOI":"10.1111\/jch.12771"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al. \n                    Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. \n                    Lancet  \n                    2005; \n                    366\n                    (9489)\n                    : 895-906.","DOI":"10.1016\/S0140-6736(05)67185-1"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Jamerson K, Weber MA, Bakris GL, et al. \n                    Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. \n                    N Engl J Med  \n                    2008; \n                    359\n                    (23)\n                    : 2417-28.","DOI":"10.1056\/NEJMoa0806182"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Falaschetti E, Mindell J, Knott C, Poulter N. \n                    Hypertension management in England: A serial cross-sectional study from 1994 to 2011. \n                    Lancet  \n                    2014; \n                    383\n                    (9932)\n                    : 1912-9.","DOI":"10.1016\/S0140-6736(14)60688-7"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, et al. \n                    A randomized trial of intensive versus standard blood-pressure control. \n                    N Engl J Med  \n                    2015; \n                    373\n                    (22)\n                    : 2103-16.","DOI":"10.1056\/NEJMoa1511939"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. \n                    Unattended blood pressure measurements in the systolic blood pressure intervention trial. \n                    Hypertension  \n                    2016; \n                    67\n                    (5)\n                    : 808-12.","DOI":"10.1161\/HYPERTENSIONAHA.116.07257"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Williamson JD, Supiano MA, Applegate WB, et al. \n                    Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 Years: A randomized clinical trial. \n                    JAMA  \n                    2016; \n                    315\n                    (24)\n                    : 2673-82.","DOI":"10.1001\/jama.2016.7050"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Palombo C, Malshi E, Morizzo C, et al. \n                    Arterial wave reflection during antihypertensive therapy with barnidipine: A 6-month, open-label study using an integrated cardiovascular ultrasound approach in patients with newly diagnosed hypertension. \n                    Clin Ther  \n                    2009; \n                    31\n                    (12)\n                    : 2873-85.","DOI":"10.1016\/j.clinthera.2009.12.011"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. \n                    Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. \n                    Lancet  \n                    2008; \n                    372\n                    (9641)\n                    : 817-21.","DOI":"10.1016\/S0140-6736(08)61171-X"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Kolloch R, Legler UF, Champion A, et al. \n                    Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: Findings from the INternational VErapamil-SR\/trandolapril STudy (INVEST). \n                    Eur Heart J  \n                    2008; \n                    29\n                    (10)\n                    : 1327-34.","DOI":"10.1093\/eurheartj\/ehn123"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"B\u00f6hm M, Swedberg K, Komajda M, et al. \n                    Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. \n                    Lancet  \n                    2010; \n                    376\n                    (9744)\n                    : 886-94.","DOI":"10.1016\/S0140-6736(10)61259-7"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Rossetti G, Pizzocri S, Brasca F, et al. \n                    Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study. \n                    Curr Ther Res Clin Exp  \n                    2008; \n                    69\n                    (3)\n                    : 192-206.","DOI":"10.1016\/j.curtheres.2008.06.002"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Pedrinelli R, Dell\u2019Omo G, Mariani M. \n                    Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension. \n                    J Hum Hypertens  \n                    2001; \n                    15\n                    (7)\n                    : 455-61.","DOI":"10.1038\/sj.jhh.1001201"},{"key":"ref45","unstructured":"Weir MR. \n                    Incidence of pedal edema formation with dihydropyridine calcium channel blockers: Issues and practical significance. \n                    J Clin Hypertens (Greenwich)  \n                    2003; \n                    5\n                    (5)\n                    : 330-5."},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Brown MJ, Palmer CR, Castaigne A, et al. \n                    Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). \n                    Lancet  \n                    2000; \n                    356\n                    (9227)\n                    : 366-72.","DOI":"10.1016\/S0140-6736(00)02527-7"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M. \n                    Initial angiotensin-converting enzyme inhibitor\/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. \n                    Am J Hypertens  \n                    2004; \n                    17\n                    (6)\n                    : 495-501.","DOI":"10.1016\/j.amjhyper.2004.02.003"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Janssen BJ, Kam KL, Smits JF. \n                    Preferential renal and mesenteric vasodilation induced by barnidipine and amlodipine in spontaneously hypertensive rats. \n                    Naunyn Schmiedebergs Arch Pharmacol  \n                    2001; \n                    364\n                    (5)\n                    : 414-21.","DOI":"10.1007\/s002100100468"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. \n                    Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. \n                    Am J Med  \n                    2011; \n                    124\n                    (2)\n                    : 128-35.","DOI":"10.1016\/j.amjmed.2010.08.007"}],"container-title":["The Open Cardiovascular Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V11\/TOCMJ-11-120\/TOCMJ-11-120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V11\/TOCMJ-11-120\/TOCMJ-11-120.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V11\/TOCMJ-11-120\/TOCMJ-11-120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T04:25:20Z","timestamp":1554870320000},"score":1,"resource":{"primary":{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/VOLUME\/11\/PAGE\/120\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,11,17]]}},"alternative-id":["TOCMJ-11-120"],"URL":"https:\/\/doi.org\/10.2174\/1874192401711010120","relation":{},"ISSN":["1874-1924"],"issn-type":[{"value":"1874-1924","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-07-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}